These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32233241)

  • 21. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of chronic administration of PDE5 combined with glycemic control on erectile function in streptozotocin-induced diabetic rats.
    Choi WS; Kwon OS; Cho SY; Paick JS; Kim SW
    J Sex Med; 2015 Mar; 12(3):600-10. PubMed ID: 25411013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
    Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
    Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PDE5 inhibitors for the management of temporary penile erectile dysfunction during treatment with assisted reproductive technology].
    Fei QJ; Pan CS; Hang XF
    Zhonghua Nan Ke Xue; 2013 Nov; 19(11):991-5. PubMed ID: 24341092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies.
    Phé V; Rouprêt M
    Diabetes Metab; 2012 Feb; 38(1):1-13. PubMed ID: 22056307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction.
    Rubio-Aurioles E; El-Meliegy A; Abdulwahed S; Henneges C; Sorsaburu S; Gurbuz S
    Curr Med Res Opin; 2015 Feb; 31(2):367-78. PubMed ID: 25068906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
    Zhang WH; Zhang XH
    Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alprostadil for the treatment of impotence.
    Hanchanale V; Eardley I
    Expert Opin Pharmacother; 2014 Feb; 15(3):421-8. PubMed ID: 24369066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors.
    El-Sakka AI
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1305-9. PubMed ID: 21846259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BPH/LUTS and ED: common pharmacological pathways for a common treatment.
    Fusco F; D'Anzeo G; Sessa A; Pace G; Rossi A; Capece M; d'Emmanuele di Villa Bianca R
    J Sex Med; 2013 Oct; 10(10):2382-93. PubMed ID: 23875757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
    Martínez-Salamanca JI; Carballido J; Eardley I; Giuliano F; Gratzke C; Rosen R; Salonia A; Stief C
    Eur Urol; 2011 Sep; 60(3):527-35. PubMed ID: 21684677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors.
    Campbell N; Clark JP; Stecher VJ; Thomas JW; Callanan AC; Donnelly BF; Goldstein I; Kaminetsky JC
    J Sex Med; 2013 Jul; 10(7):1842-9. PubMed ID: 23634714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
    McCabe MP; Althof SE
    J Sex Med; 2014 Feb; 11(2):347-63. PubMed ID: 24251371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
    Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
    J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.